LLY

#11
Eli Lilly and Company Common Stock
1074.1 0 USD
-2.83%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
1 073.01
1 076.49
1年のレンジ
644.51
1 149.10
1日の変化
-2.83%
月次変化
+12.08%
6か月変化
+2.02%
1年の変化
+46.20%
以前の終値
1105.3 7
Open
1075.0 2
安値
1073.0 1
High
1076.4 9
ボリューム
150
チャート全体を表示 Full chart

Financials

概要 明細書 統計 配当金
期次 年次
  • Market Capitalization 1.01 T
  • Employee 50 K
  • Founded N/A
  • CEO David A. Ricks
  • Website www.lilly.com
  • Headquarter Indiana, United States
  • FIGI BBG000BNBDC2
  • Industry 医薬品メーカー（一般）
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
32.67
売上高対価格比率
11.44
1株当たり配当金
—
配当利回り（％）
—

Eli Lilly and Company Common Stock

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes.

ニュース